Novartis has provided updated data from phase 3 trials of ZOLGENSMA (onasemnogene abeparvovec-xioi) for patients with spinal muscular atrophy. …
Latest Video
New Stories
-
Current approach to HTA is the barrier to personalised medicine, not the health system
December 9, 2019 - - Latest News -
David Thomas: Matching the new world to an old system
December 9, 2019 - - Latest News -
'This is simply the way it has to be'
December 9, 2019 - - Latest News -
NZ Coroner opens inquiry into forced switch
December 9, 2019 - - Latest News -
New leadership for Mundipharma ANZ with Jane Orr announcing retirement
December 6, 2019 - - Latest News -
AusBiotech 'astonished' after R&D tax cut legislation tabled on final day
December 6, 2019 - - Latest News -
GSK welcomes new approvals for asthma biologic
December 6, 2019 - - Latest News